Corrections:

Aimin Qiao^1,*, Kuansong Wang^4,5,*, Yunsheng Yuan^7,*, Yidi Guan², Xingcong Ren³, Lanya Li², Xisha Chen², Feng Li², Alex F. Chen^8,9, Jianda Zhou⁶, Jin-Ming Yang³ and Yan Cheng²

¹ Center for Bioresources and Drug Discovery and School of Bioscience and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, China
²Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Changsha 410008, China
³Department of Pharmacology, The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine and Milton S. Hershey Medical Center, Hershey, PA 17033, USA
⁴Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China
⁵Department of Pathology, Basic Medical School, Central South University, Changsha 410008, China
⁶Department of Plastic Surgery, The Third Xiangya Hospital, Central South University, Changsha 410008, China
⁷Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China
⁸Center for Vascular and Translational Medicine, The College of Pharmacy, Central South University, Changsha 410013, China
⁹The Third Xiangya Hospital, Central South University, Changsha 410013, China
^*These authors contributed equally to this work

Published: June 05, 2018

This article has been corrected: The correct figure 5A cell line T98G is given below:
The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:43390-43400. DOI: https://doi.org/10.18632/oncotarget.9717.

Figure 5: Suppression of Sirt3 augments the activation of apoptosis and increases the sensitivity of tumor cells to hypoxia. (A) LN229 and T98G cells were transfected with a non-targeting RNA or a siRNA targeting Sirt3, followed by hypoxia treatment for 48h. Apoptosis was determined by flow cytometric analyses of Annexin staining.